ArticlesFluorocarbon Aerosol Propellents X: Pharmacokinetics of dichlorotetrafluoroethane (cas 1320-37-2) in Dogs

Add time:08/21/2019    Source:sciencedirect.com

An intravenous dosage form of dichlorotetrafluoroethane (cas 1320-37-2), a common fluorocarbon aerosol propellant, was formulated in polyethylene glycol 400 for single dosing to unanesthetized dogs. A three‐compartment open model was proposed for the disposition of this compound in dogs, with average half‐lives of 1.3, 9.6, and 50.8 min for the three disposition phases. An analysis of tissue compartment distribution following a single dose showed that it took about 2 hr to achieve pseudo‐distribution equilibration, following which more than 90% of the propellant remaining in the body was retained in the tissue compartments. Pulmonary clearance and volumes of distribution were calculated considering the first‐pass effect through the lungs. The volume of distribution was approximately 10 times the body weight in terms of blood concentration, and about 84% of the propellant was cleared from the blood passing through the lungs in each cycle.

We also recommend Trading Suppliers and Manufacturers of dichlorotetrafluoroethane (cas 1320-37-2). Pls Click Website Link as below: cas 1320-37-2 suppliers

Prev:Regular ArticleCatalytic Hydrodechlorination of 1,1-dichlorotetrafluoroethane (cas 1320-37-2) by Pd/Al2O3
Next:Regular ArticleHydrodechlorination of dichlorodifluoromethane over palladium model catalysts and a comparison with the hydrodechlorination of 1,1-dichlorotetrafluoroethane (cas 1320-37-2))